BACKGROUND: Despite the high prevalence of respiratory symptoms and obstructive lung disease in HIV-infected subjects, the prevalence of bronchodilator reversibility (BDR) and asthma has not been systematically studied during the era of combination antiretroviral therapy (ART). OBJECTIVE: We sought to determine the prevalence of asthma diagnosis and related pulmonary function abnormalities in an HIV-infected cohort and to identify potential mechanisms. METHODS: We performed a cross-sectional analysis of 223 HIV-infected subjects with data on respiratory symptoms and diagnoses, pulmonary function, sputum cell counts, and asthma-related cytokines and chemokines in serum/sputum. RESULTS: Doctor-diagnosed asthma was present in 46 (20.6%), and BDR (≥200 mL and ≥12% increase in FEV(1) or forced vital capacity) was present in 20 (9.0%) participants. Pulmonary symptoms and function were worse in those with doctor-diagnosed asthma. Doctor-diagnosed asthma was independently associated with female sex (P = .04), body mass index of greater than 29.6 kg/m(2) (vs <29.6 kg/m(2), P = .03), history of bacterial or Pneumocystis pneumonia (P = .01), and not currently taking ART (P = .04) and in univariate analysis with parental history of asthma (n = 180, P = .004). High sputum eosinophil percentages (>2.3% based on the highest decile) were more likely in those with doctor-diagnosed asthma (P = .02) or BDR (P = .02). Doctor-diagnosed asthma tended to be more common with high sputum IL-4 (P = .02) and RANTES (P = .02) levels, whereas BDR was associated with high plasma macrophage inflammatory protein 1α (P = .002) and sputum macrophage inflammatory protein 1β (P = .001) levels. CONCLUSION: Asthma diagnosis and BDR are prevalent in an HIV-infected outpatient cohort, and associations with family history, obesity, allergic inflammation, prior infection, absence of ART, and increased HIV-stimulated cytokines suggest possible mechanisms of HIV-associated asthma.
BACKGROUND: Despite the high prevalence of respiratory symptoms and obstructive lung disease in HIV-infected subjects, the prevalence of bronchodilator reversibility (BDR) and asthma has not been systematically studied during the era of combination antiretroviral therapy (ART). OBJECTIVE: We sought to determine the prevalence of asthma diagnosis and related pulmonary function abnormalities in an HIV-infected cohort and to identify potential mechanisms. METHODS: We performed a cross-sectional analysis of 223 HIV-infected subjects with data on respiratory symptoms and diagnoses, pulmonary function, sputum cell counts, and asthma-related cytokines and chemokines in serum/sputum. RESULTS: Doctor-diagnosed asthma was present in 46 (20.6%), and BDR (≥200 mL and ≥12% increase in FEV(1) or forced vital capacity) was present in 20 (9.0%) participants. Pulmonary symptoms and function were worse in those with doctor-diagnosed asthma. Doctor-diagnosed asthma was independently associated with female sex (P = .04), body mass index of greater than 29.6 kg/m(2) (vs <29.6 kg/m(2), P = .03), history of bacterial or Pneumocystis pneumonia (P = .01), and not currently taking ART (P = .04) and in univariate analysis with parental history of asthma (n = 180, P = .004). High sputum eosinophil percentages (>2.3% based on the highest decile) were more likely in those with doctor-diagnosed asthma (P = .02) or BDR (P = .02). Doctor-diagnosed asthma tended to be more common with high sputum IL-4 (P = .02) and RANTES (P = .02) levels, whereas BDR was associated with high plasma macrophage inflammatory protein 1α (P = .002) and sputum macrophage inflammatory protein 1β (P = .001) levels. CONCLUSION:Asthma diagnosis and BDR are prevalent in an HIV-infectedoutpatient cohort, and associations with family history, obesity, allergic inflammation, prior infection, absence of ART, and increased HIV-stimulated cytokines suggest possible mechanisms of HIV-associated asthma.
Authors: J Belda; R Leigh; K Parameswaran; P M O'Byrne; M R Sears; F E Hargreave Journal: Am J Respir Crit Care Med Date: 2000-02 Impact factor: 21.405
Authors: J V Fahy; H A Boushey; S C Lazarus; E A Mauger; R M Cherniack; V M Chinchilli; T J Craig; J M Drazen; J G Ford; J E Fish; E Israel; M Kraft; R F Lemanske; R J Martin; D McLean; S P Peters; C Sorkness; S J Szefler Journal: Am J Respir Crit Care Med Date: 2001-05 Impact factor: 21.405
Authors: A Spanevello; M Confalonieri; F Sulotto; F Romano; G Balzano; G B Migliori; A Bianchi; G Michetti Journal: Am J Respir Crit Care Med Date: 2000-09 Impact factor: 21.405
Authors: P T Diaz; M A King; E R Pacht; M D Wewers; J E Gadek; H N Nagaraja; J Drake; T L Clanton Journal: Ann Intern Med Date: 2000-03-07 Impact factor: 25.391
Authors: Janice K Louie; Ling Chin Hsu; Dennis H Osmond; Mitchell H Katz; Sandra K Schwarcz Journal: J Infect Dis Date: 2002-09-13 Impact factor: 5.226
Authors: M Grob; P Schmid-Grendelmeier; H I Joller-Jemelka; E Ludwig; R W Dubs; P J Grob; B Wüthrich; L R Bisset Journal: Allergy Date: 2003-03 Impact factor: 13.146
Authors: Taylor Eddens; Waleed Elsegeiny; Michael P Nelson; William Horne; Brian T Campfield; Chad Steele; Jay K Kolls Journal: J Immunol Date: 2015-05-20 Impact factor: 5.422
Authors: William T Shearer; Denise L Jacobson; Wendy Yu; George K Siberry; Murli Purswani; Suzanne Siminski; Laurie Butler; Erin Leister; Gwendolyn Scott; Russell B Van Dyke; Ram Yogev; Mary E Paul; Ana Puga; Andrew A Colin; Meyer Kattan Journal: J Allergy Clin Immunol Date: 2017-03-06 Impact factor: 10.793
Authors: Gerald S Bloomfield; Prateeti Khazanie; Alison Morris; Cristina Rabadán-Diehl; Laura A Benjamin; David Murdoch; Virginia S Radcliff; Eric J Velazquez; Charles Hicks Journal: J Acquir Immune Defic Syndr Date: 2014-09-01 Impact factor: 3.731
Authors: Meghan E Fitzpatrick; Mehdi Nouraie; Matthew R Gingo; Danielle Camp; Cathy J Kessinger; James B Sincebaugh; Andrew Clarke; John W Ries; Eric C Kleerup; Lawrence Kingsley; Alison Morris Journal: AIDS Date: 2016-06-01 Impact factor: 4.177